Skip to main content

Gene Therapy Deal Benchmarks in Metabolic & Obesity

Median Upfront
$669M
Range: $367M - $959M
Total Deal Value
$3.2B
Range: $2.1B - $4.3B
Royalty Rate
14.5% - 26.5%
Tiered up to 30.5%
Dev Milestones
$451M
Range: $305M - $598M
Model Your Deal

Market Analysis

Gene Therapy therapies in metabolic & obesity have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 gene therapy asset in metabolic & obesity is $669M, with total deal values reaching $3.2B. Development milestones average $451M, while regulatory milestones contribute $551M.

The metabolic & obesity gene therapy landscape is characterized by extremely high competitive intensity driven by the GLP-1 revolution and massive obesity market opportunity. Oral formulations, dual/triple incretins, and muscle-sparing approaches command unprecedented deal valuations. The recommended deal structure allocates approximately 21% to upfront payments and 79% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for gene therapy metabolic & obesity deals range from 14.5% to 26.5% at the base tier, with tiered escalation reaching 18.5%-30.5% on blockbuster sales. Commercial milestones averaging $1.5B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a gene therapy metabolic & obesity licensing deal?
Based on our analysis, Phase 2 gene therapy licensing deals in metabolic & obesity average $669M in upfront payments, with a range of $367M to $959M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for gene therapy metabolic & obesity transactions?
The median total deal value for Phase 2 gene therapy assets in metabolic & obesity is $3.2B, ranging from $2.1B to $4.3B. This includes development milestones ($451M), regulatory milestones ($551M), and commercial milestones ($1.5B).
What royalty rates are standard for gene therapy deals in metabolic & obesity?
Base royalty rates for gene therapy metabolic & obesity transactions range from 14.5% to 26.5%, with tiered escalations reaching 18.5%-30.5% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in gene therapy metabolic & obesity deals?
Gene Therapy metabolic & obesity deals allocate approximately 79% of total deal value to milestones. Development milestones ($451M) make up the largest share, followed by commercial milestones ($1.5B) and regulatory milestones ($551M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Metabolic & Obesity

View

GLP-1 Agonist in Metabolic & Obesity

View

Gene Therapy in Oncology

View

Gene Therapy in Neurology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included